- Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates
- Zai Lab Announces Participation in November Investor Conferences
- Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Corporate Updates on November 7, 2023
- Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China
- Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China
- Zai Lab Announces Participation in September Investor Conferences
- Zai Lab Announces Second Quarter 2023 Financial Results and Corporate Updates
- Zai Lab to Announce Second Quarter 2023 Financial Results and Corporate Updates on August 7, 2023
- JAMA Oncology Publishes Data from Zai Lab Study Demonstrating Significant Reduction in Disease Progression or Death with ZEJULA (Niraparib) Maintenance Therapy in Broad Population of Advanced Ovarian Cancer Patients
- Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
More ▼
Key statistics
On Friday, Zai Lab Ltd (1ZL:FRA) closed at 15.20, 22.58% above the 52 week low of 12.40 set on Apr 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 15.20 |
---|---|
High | 15.20 |
Low | 15.20 |
Bid | 14.80 |
Offer | 15.30 |
Previous close | 15.60 |
Average volume | 330.50 |
---|---|
Shares outstanding | 99.21m |
Free float | 89.91m |
P/E (TTM) | -- |
Market cap | 1.63bn USD |
EPS (TTM) | -3.46 USD |
Data delayed at least 15 minutes, as of May 03 2024 07:05 BST.
More ▼